Institutes for Systems Genetics, West China Hospital
Copyright @ 2022 ISG. All Rights Reserved.
ncRNA name
hsa-miR-3619-5p
Specific or universal ncRNAs
Specific ncRNAs
Class
MicroRNA
Biomarker
Yes
Biomarker application
Treatment
Upstream regulatory factors
Not available
Downstream target
KPNA4
Cancer name
Cutaneous Squamous-Cell Carcinoma
Cancer site
Skin
Treatment type
Chemotherapy
Drug
Cisplatin
Impact of wild-type ncRNA on chemotherapy resistance
Down
Impact of knockdown of ncRNA on chemotherapy resistance
Impact of overexpression of ncRNA on chemotherapy resistance
ncRNA differential expression in
cancer
patients vs. healthy people
Not available
Number of patients
Not available
Male patients
Not available
Female patients
Not available
Age range and number
Not available
PMID
Description
MiR-3619-5p inhibited cell proliferation and cisplatin resistance of CSCC by regulating KPNA4 expression, suggesting that miR-3619-5p/KPNA4 pathway may represent a potential promising strategy for the treatment of patients with CSCC.
Tissue resource
human benign epidermal keratinocyte cell lines HaCaT
human cutaneous squamous-cell carcinoma cell lines A431
human cutaneous squamous-cell carcinoma cell lines HSC-5
human cutaneous squamous-cell carcinoma cell lines SCC13
human cutaneous squamous-cell carcinoma cell lines Tca8113
Experiment
qPCR,Western blot,Dual-luciferase reporter assay
Institute
the Cell Bank of the Chinese Academy of Sciences
Country
China
Continent
Asia
Institutes for Systems Genetics, West China Hospital
Copyright @ 2022 ISG. All Rights Reserved.